24 completed, 7 active not recruiting, 4 recruiting, 3 terminated. 45 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 45 | Completed 24, Active not recruiting 7, Recruiting 4, Terminated 3, Suspended 2, Unknown 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 2 | 6 | Completed 4, Suspended 1, Terminated 1 |
Follow Carcinoma in Situ: new trials by email Literature Review of Carcinoma in Situ trials Research Report on Carcinoma in Situ
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) Radiation Therapy, Standard of Care Radiation Therapy, No Intervention - Breast Cancer | Phase 3 | Not yet recruiting | NRG Oncology | 5270 | 2027-01-30 | 2026-09-30 |
| Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery Adjuvant Radiotherapy, tamoxifen - Ductal Carcinoma In Situ, DCIS | Phase 3 | Recruiting | Fudan University | 636 | 2026-07-01 | 2026-08-13 |
| Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer TARA-002, Investigator's Choice of Intravesical Chemotherapy - Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma | Phase 3 | Recruiting | Protara Therapeutics | 284 | 2026-05-29 | 2026-10-06 |
| Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial Anastrozole, Letrozole, Exemestane - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8 | Phase 3 | Suspended | Alliance for Clinical Trials in Oncology | 1556 | 2025-02-19 | 2026-09-02 |
| Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel Cimetidine, Dexamethasone, Diphenhydramine - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2 / Phase 3 | Completed | Ohio State University Comprehensive Cancer Center | 130 | 2021-10-07 | 2025-08-20 |
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside - Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | Phase 3 | Active not recruiting | CG Oncology, Inc. | 190 | 2020-10-27 | 2026-07-10 |
| Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ Delayed SLND, Late SLND - DCIS, Breast Cancer | Phase 3 | Recruiting | Uppsala University | 500 | 2020-03-01 | 2023-08-03 |
| Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ Low-dose tamoxifen, Whole breast radiotherapy - Breast Ductal Carcinoma in Situ | Phase 3 | Unknown | National Taiwan University Hospital | 810 | 2019-04-30 | 2019-08-06 |
| Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) 9vHPV vaccine - Papillomavirus Infections, Uterine Cervical Neoplasms | Phase 3 | Completed | Merck Sharp & Dohme LLC | 201 | 2018-06-29 | 2020-02-25 |
| Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Educational Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis - Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm | Phase 3 | Completed | Children's Oncology Group | 299 | 2017-11-29 | 2026-07-24 |
| Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration - Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma | Phase 2 / Phase 3 | Suspended | M.D. Anderson Cancer Center | 928 | 2017-03-06 | 2026-09-14 |
| Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation - Breast Carcinoma In Situ, Invasive Breast Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1195 | 2017-01-18 | 2026-10-26 |
| Oxybutynin Chloride in Managing Hot Flashes Oxybutynin Chloride, Placebo, Quality-of-Life Assessment - Breast Carcinoma, Ductal Breast Carcinoma In Situ | Phase 3 | Completed | Academic and Community Cancer Research United | 150 | 2016-12-09 | 2020-01-18 |
| Breast Cancer WEight Loss Study (BWEL Study) Health Education Program, Weight Loss Intervention - Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 3177 | 2016-09-16 | 2026-09-02 |
| RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE) Synergo® RITE + MMC - Bladder Cancer | Phase 3 | Withdrawn | Medical Enterprises Europe B.V. | 2016-09-01 | 2018-05-07 | |
| Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer metformin hydrochloride, placebo - Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 86 | 2015-11-23 | 2026-10-08 |
| Therapeutic Nipple Sparing Mastectomy. Nipple sparing mastectomy - Breast Cancer | Phase 3 | Completed | Institut Claudius Regaud | 450 | 2015-02-09 | 2026-04-14 |
| Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer CG0070 Adenovirus Vector, Control Arm: Quadruple Choice - Transitional Cell Carcinoma, Bladder Cancer | Phase 2 / Phase 3 | Terminated | CG Oncology, Inc. | 22 | 2014-03-01 | 2021-04-14 |
| Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Insertion of suction drain(s) following mastectomy, Adaptive skin sutures. - in Situ Breast Cancer, Invasive Breast Cancer | Phase 3 | Unknown | National Institute of Oncology, Hungary | 400 | 2011-09-01 | 2015-10-06 |
| Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost - Breast Cancer | Phase 3 | Active not recruiting | Radiation Therapy Oncology Group | 2354 | 2011-05-24 | 2026-03-05 |
Showing 20 of 45. Sign in to see all of them.
Breast Neoplasms (24) · Carcinoma, Intraductal, Noninfiltrating (23) · Breast Carcinoma In Situ (18) · Urinary Bladder Neoplasms (8) · Neoplasms (7) · Carcinoma, Transitional Cell (4) · Non-Muscle Invasive Bladder Neoplasms (4) · Neoplasm Recurrence, Local (3) · Breast Neoplasms, Male (2) · Carcinoma, Ductal, Breast (2) · Endometrial Neoplasms (2) · Hot Flashes (2) · Mycobacterium Infections (2) · Neoplasms by Site (2)
Carcinoma (45) · Neoplasms by Histologic Type (45) · Neoplasms, Glandular and Epithelial (45) · Neoplasms (38) · Neoplasms by Site (36) · Skin Diseases (28) · Skin and Connective Tissue Diseases (28) · Adenocarcinoma (27) · Breast Diseases (27) · Neoplasms, Ductal, Lobular, and Medullary (25) · Breast Carcinoma In Situ (12) · Urogenital Diseases (12) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11)
Tamoxifen (10) · Anastrozole (4) · Radiotherapy (4) · Letrozole (3) · valrubicin (3) · Chemotherapy, Adjuvant (2) · Early Intervention, Educational (2) · Medroxyprogesterone (2) · Mitomycin (2) · exemestane (2) · Absorptiometry, Photon (1) · CT-P6 (1) · Calcium Dobesilate (1) · Cimetidine (1) · Counseling (1)
Alliance for Clinical Trials in Oncology (3) · National Cancer Institute (NCI) (3) · Bioniche Life Sciences Inc. (2) · CG Oncology, Inc. (2) · ETOP IBCSG Partners Foundation (2) · Endo USA Inc., a Keenova Therapeutics Company (2) · M.D. Anderson Cancer Center (2) · Radiation Therapy Oncology Group (2) · Academic and Community Cancer Research United (1) · Andrea DeCensi (1) · Children's Oncology Group (1) · Eastern Cooperative Oncology Group (1) · Ente Ospedaliero Ospedali Galliera (1) · Fudan University (1) · GTx (1)
United States (29) · Canada (12) · France (6) · Puerto Rico (6) · Switzerland (5) · South Korea (4) · Germany (3) · Italy (3) · Sweden (3) · Australia (2) · Hong Kong (2) · Hungary (2) · Ireland (2) · Japan (2) · Poland (2)
Barbara L. Smith, MD, PhD (2) · Akos Savolt, M.D. (1) · Alex W Yeung, MBBS (1) · Alvaro Morales, MD (1) · Andrea De Censi, MD (1) · Andrea DeCensi, MD (1) · Andreas Karakatsanis, PhD (1) · Anthony Howell (1) · Beat Thurlimann, MD (1) · Benjamin D Smith (1) · Beryl McCormick, MD (1) · C. Rageth, MD, PD (1) · Charles Leonard, MD (1) · Charles Loprinzi (1)
PMID 23984897, PMID 14962527, PMID 16382061, PMID 16730270, PMID 17200148, PMID 17301074, PMID 17492927, PMID 17679725, PMID 17912636, PMID 17998546, PMID 18083065, PMID 18279765, PMID 18332471, PMID 18364505, PMID 18981464, PMID 19031925, PMID 19096768, PMID 19243946, PMID 19474112, PMID 19528136, PMID 19692688, PMID 20144231, PMID 20385495, PMID 20800381, PMID 20888137, PMID 21046229, PMID 21321298, PMID 21335417, PMID 21566413, PMID 21635709, PMID 21892704, PMID 21986093, PMID 22003243, PMID 22018631, PMID 22395644, PMID 22480131, PMID 23106852, PMID 23295793, PMID 24305979, PMID 24320967, PMID 25286009, PMID 25605856, PMID 25935582, PMID 26215945, PMID 26387144, PMID 26540028, PMID 26590813, PMID 26633571, PMID 27020837, PMID 27217455
U10CA032102 (2), U10CA180868 (2), U10CA180888 (2), 2017 (1), P01CA106451 (1), P30CA015083 (1), P30CA051008 (1), R01CA074861 (1), R01CA108933 (1), R01CA193478 (1), U10CA012027 (1), U10CA031946 (1), U10CA037429 (1), U10CA180821 (1), U10CA180830 (1)